Press Releases
Looking for more press releases? Explore our full press release archive by date to access past announcements, news updates, and media releases published on Healthcare News Netherlands.
![[Latest] Global Electrolyte Drinks Market Size/Share Worth USD 63 Billion by 2034 at a 5.5% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)](/images/pressrelease-small.png)
[Latest] Global Electrolyte Drinks Market Size/Share Worth USD 63 Billion by 2034 at a 5.5% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)
GlobeNewswire, Inc.
·
July 7, 2025
Austin, TX, USA, July 07, 2025 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Electrolyte Drinks Market Size, Trends and Insights By Type (Isotonic Drinks, Hypotonic Drinks, Hypertonic Drinks), By End-Use...
Primo Biotechnology Secures A Funding and Targets 2026 IPO to Strengthen Global Radiopharmaceutical Strategy
GlobeNewswire, Inc.
·
July 2, 2025
TAIPEI, Taiwan, July 02, 2025 (GLOBE NEWSWIRE) -- Primo Biotechnology Co., Ltd., a pioneering radiopharmaceutical company in Taiwan, announced the successful completion of its NT$220 million Series A funding round. With total capital raised now...
Ipsen receives CHMP positive opinions for Iqirvo® (elafibranor) in Primary Biliary Cholangitis and Kayfanda® (odevixibat) in Alagille Syndrome, two rare cholestatic liver diseases
GlobeNewswire, Inc.
·
July 26, 2024
Ipsen receives CHMP positive opinions for Iqirvo® (elafibranor) in Primary Biliary Cholangitis and Kayfanda® (odevixibat) in Alagille Syndrome, two rare cholestatic liver diseases CHMP positive opinion for Iqirvo® (elafibranor) recommended for the...
ONWARD® Medical Reaffirms 2024 Strategic Priorities and Releases Unaudited Q2 Financial Highlights
GlobeNewswire, Inc.
·
August 5, 2024
Company expects to commercialize the investigational ARC-EX® System in Q4 2024 and has commenced launch preparations Company preparing to initiate global pivotal trial for investigational ARC-IM® Therapy to address blood pressure instability after...
Europe Medical Cannabis Oil Market Poised for Significant Growth: From US$ 905.56 Million in 2023 | Astute Analytica
EIN Presswire
·
July 31, 2024
The European medical cannabis oil market is set to experience robust expansion with a projected CAGR of 12.8% during the forecast period 2024–2032. CHICAGO, UNITED STATES, July 31, 2024 /EINPresswire.com/ -- The 𝐄𝐮𝐫𝐨𝐩𝐞 𝐦𝐞𝐝𝐢𝐜𝐚𝐥 𝐜𝐚𝐧𝐧𝐚𝐛𝐢𝐬 𝐨𝐢𝐥...
Tonix Pharmaceuticals Presented Data and Analyses of TNX-102 SL Treatment Effects on Fibromyalgia, the Prototypic Nociplastic Pain Syndrome, at the IASP 2024 World Congress on Pain
GlobeNewswire, Inc.
·
August 12, 2024
Bedtime TNX-102 SL (sublingual cyclobenzaprine HCl) treatment in the Phase 3 RESILIENT study resulted in statistically significant improvement in the primary endpoint of fibromyalgia nociplastic pain and in all six key secondary endpoints,...
CEOs unite at The Consumer Goods Forum’s Global Summit to accelerate impact across the industry
EIN Presswire
·
June 13, 2025
AMSTERDAM, NETHERLANDS, June 13, 2025 /EINPresswire.com/ -- The Consumer Goods Forum’s (CGF’s) 2025 Global Summit, the landmark annual event uniting CEOs and thought leaders from across the consumer sector and beyond, drew to a close today in...
Whispp earns a spot on the 2025 Forbes Accessibility 100
EIN Presswire
·
June 18, 2025
Whispp’s on-device, assistive voice AI technology is a genuine breakthrough, instantly converting whispered and impaired speech into a speaker’s natural voice LEIDEN, NETHERLANDS, June 18, 2025 /EINPresswire.com/ -- Whispp, the Dutch assistive...
Surge of Preventative Healthcare Driving Nutraceuticals Market at 9.50% CAGR by 2031
EIN Presswire
·
August 9, 2024
WESTFORD, MASSACHUSETTS, UNITED STATES, August 9, 2024 /EINPresswire.com/ -- Nutraceuticals Market size was valued at USD 383.69 billion in 2022 and is poised to grow from USD 420.14 billion in 2023 to USD 868.38 billion by 2031, growing at a...
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire, Inc.
·
August 2, 2024
NAARDEN, The Netherlands and MIAMI, Aug. 02, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for...
Pet Insurance Market Next Big Thing | Major Giants- Embrace, Pumpkin, Healthy Paws
EIN Presswire
·
August 21, 2024
Stay up to date with Pet Insurance Market research offered by HTF MI. Check how key trends and emerging drivers are shaping this industry growth. PUNE, MAHARASHTRA, INDIA, August 21, 2024 /EINPresswire.com/ -- According to HTF Market...
$3.2+ Billion Worldwide Athleisure Market Grow at CAGR of 5.2% from 2023 to 2032 : Rise in Health and Wellness Trends
EIN Presswire
·
August 22, 2024
The Athleisure Market Size was valued at $2 billion in 2022, and is estimated to reach $3.2 billion by 2032, growing at a CAGR of 5.2% from 2023 to 2032. WILMINGTON, DELAWARE , UNITED STATES, August 22, 2024 /EINPresswire.com/ -- Athleisure...
NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter Financial Results
GlobeNewswire, Inc.
·
August 7, 2024
-- Reported positive topline data from pivotal Phase 3 BROOKLYN trial evaluating obicetrapib in patients with HeFH; achieved primary endpoint of LS mean reduction in LDL-C versus placebo, as well as statistically significant reductions in other...
AVITA Medical Expands Portfolio with Unique Dermal Matrix to Advance Wound Care
GlobeNewswire, Inc.
·
July 31, 2024
VALENCIA, Calif., July 31, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care management and skin restoration, today announced it...
Sexually Transmitted Diseases Diagnostics Market to Set Phenomenal Growth | Abbott Laboratories,Hologic
EIN Presswire
·
July 23, 2024
The Sexually Transmitted Diseases Diagnostics market size is estimated to increase by USD at a CAGR of 7.19% by 2030. PUNE, MAHARASHTRA, INDIA, July 23, 2024 /EINPresswire.com/ -- According to HTF Market Intelligence, the Global Sexually...
Food Enzymes Market to Hit $3.1 billion by 2026 | Key Companies Included - DuPont (US), DSM (Netherlands), Novozymes (US), Kerry Group (Ireland) & Others
GlobeNewswire, Inc.
·
August 20, 2024
Chicago, Aug. 20, 2024 (GLOBE NEWSWIRE) -- The food enzymes market size is estimated to be valued at USD 2.2 billion in 2021 and is projected to reach USD 3.1 billion by 2026, recording a CAGR of 6.4%, in terms of value. The growing demand for...
Cognition Therapeutics to Host Investor Webcast to Discuss Results from Proof-of-Concept Phase 2 SHINE Study of CT1812 in Mild-to-Moderate Alzheimer’s Disease at 8:30am ET on Monday July 29, 2024
GlobeNewswire, Inc.
·
July 26, 2024
PURCHASE, N.Y., July 26, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical stage company developing drugs that treat neurodegenerative disorders will host an investor webcast on Monday,...
NewAmsterdam Pharma to Announce Topline Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia on Monday, July 29, 2024
GlobeNewswire, Inc.
·
July 26, 2024
NAARDEN, the Netherlands and MIAMI, July 26, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for...
MetAlert Continues to Expand Distribution with New SmartSole Distributor in Mexico and Trials being Conducted in Spain, Portugal and Netherlands
GlobeNewswire, Inc.
·
August 15, 2024
LOS ANGELES, CALIFORNIA, Aug. 15, 2024 (GLOBE NEWSWIRE) -- MetAlert, Inc. (OTC: MLRT) (“the Company”), a pioneer in GPS wearable technology and a global provider in the field of human and asset tracking and recovery systems, announced today it has...
CervoMed Announces Presentation at AAIC 2024 on Plasma Biomarker Data That Are Consistent with Neflamapimod Impacting the Underlying Disease Process in Patients with Dementia with Lewy bodies (DLB)
GlobeNewswire, Inc.
·
July 29, 2024
- Baseline data from the AscenD-LB Phase 2a trial in DLB demonstrated that plasma glial fibrillary acidic protein (GFAP) was highly correlated to scores on the CDR-SB; plasma GFAP shown to increase with neurodegenerative progression in DLB – -...